DC-CIK细胞免疫对晚期三阴性乳腺癌疗效及死亡率的影响

Effect of DC-CIK Cell Immunization on the Curative Effect and Mortality of Advanced Three Negative Breast Cancer

目的探讨DC-CIK细胞免疫治疗对晚期三阴性乳腺癌疗效及死亡率的影响。方法40例晚期三阴性乳腺癌患者,根据治疗方法分为对照组(n=20例)和研究组(n=20例),对照组给予常规化疗联合靶向治疗;研究组在对照组的基础上给予自体DC-CIK细胞免疫治疗,比较两组临床疗效,治疗后不良发应。随访2~4年,统计两组治疗后1年、3年生存率/死亡率,及两组治疗后免疫功能和生活质量的变化。结果对照组和研究组的ORR分别为55%和30.00%,DCR分别为85.00%和70.00%,研究组的ORR及DCR均明显高于对照组(P<0.05),两组治疗后均出现不同程度的发热,恶心、呕吐等肠胃异常及其他不良反应,但两组相比差异无统计学意义(P>0.05)。治疗后研究组CD3^+、CD3^+/CD4^+、CD3^+/CD8^+、CD4^+/CD8^+水平均明显上升(P<0.05);而对照组治疗后CD3^+、CD3^+/CD4^+、CD3^+/CD8^+、CD4^+/CD8^+水平均显著下降(P<0.05)。同时两组治疗后1个月、3个月、6个月,两组KPS评分均显著升高,且研究组的KPS评分显著高于对照组(P<0.05),随访2~4年,截止到2017年12月,研究的全因死亡率为30%显著低于对照组的45.00%(χ^2=4.800,P<0.05);研究组治疗后1年和3年生存率为85.00%(17/20)和65.00%(13/20);明显高于对照组的70.00%(14/20)和55.00%(11/20)(P<0.05)。结论DC-CIK细胞免疫治疗联合常规化疗及靶向治疗,可有效控制病情发展,增强免疫力,提高患者生存质量,延长患者生存时间。

Objective To investigate the effect of Curative effect and mortality on DC-CIK cells immunotherapy for advanced three negative breast cancer.Methods 40 patients with three negative breast cancer were selected.According to the methods of treatment,all patients were divided into the control group(n=20 cases)and the study group(n=20 cases),the control group was given conventional chemotherapy combined with targeted therapy;the study group received autologous DC-CIK cell treatment on the basis of the control group.Compared the clinical efficacy,the adverse between the 2 groups,and followed up for 2~4 years,statistics of the 2 groups after treatment 1-,3-year survival rates and mortality,and the 2 groups after treatment of immune function and quality of life.Results The ORR in the study group and the control group were respectively 55%and 30%,the DCR were respectively 85%and 70%,ORR and DCR of the study group were significantly higher than the control group(P<0.05).The 2 groups have fever,nausea and vomiting in different degrees after treatment,such as gastrointestinal dysfunction and other adverse reactions,but the 2 groups had no statistical difference(P>0.05).The levels of CD3^+,CD3^+/CD4^+,CD3^+/CD8^+,CD4^+/CD8^+in study group were significantly increased(P<0.05)after treatment;while the control group the levels of CD3^+,CD3^+/CD4^+,CD3^+/CD8^+,CD4^+/CD8^+were significantly decreased after treatment(P<0.05).At the same time,the 2 groups after 1 months,3 months,6 months,the KPS score of the 2 groups increased significantly,and the study group KPS scores were significantly higher than those of the control group(P<0.05),followed up for 2~4 years,by the end of December 2017,the all-cause mortality was 30%lower than the control group 45%(χ^2=4.800,P<0.05);the study group after treatment for 1-and 3-year survival rates were 85%(17/20)and 65.00%(13/20);significantly higher than 70%(14/20)and 55%(11/20)(P<0.05)of the control group.Conclusion DC-CIK cell immunotherapy combined with conventional chemotherapy and targeted therapy can effectively control the development of the disease,enhance immunity,improve the quality of life and prolong the survival time of patients.